PENGARUH KEMOTERAPI NEOADJUVAN BERBASIS TAKSAN DAN ANTRASIKLIN TERHADAP UKURAN TUMOR, STATUS KELENJAR GETAH BENING DAN KADAR ESTRADIOL PADA KASUS KANKER PAYUDARA STADIUM LOKAL LANJUT DENGAN HORMON RESEPTOR POSITIF (LUMINAL A) PADA USIA PREMENOPOSE

Erwin Fajar, Rudy Thabry, Yadi Yadi

Abstract


Abstrak

Latar Belakang: Kanker yang paling banyak menyerang wanita di Indonesia adalah kanker payudara, menduduki peringkat satu di Indonesia, Tingginya angka kejadian kanker payudara sebagai penyebab kematian adalah akibat dari banyaknya jumlah pasien kanker yang baru datang dengan stadium lanjut. Locally Advanced Breast Cancer atau Kanker payudara stadium lokal lanjut meliputi tumor dengan ukuran T3 dan T4, yang memiliki keterlibatan luas nodus regional (N2 atau N3), dan kanker payudara inflamasi. Dimana pada kasus tersebut membutuhkan penanganan agresif, termasuk kemoterapi neoadjuvan berbasis taksan dan antrasiklin. Penelitian ini bertujuan untuk mengevaluasi pengaruh kemoterapi tersebut terhadap ukuran tumor, status kelenjar getah bening, dan kadar Estradiol.

Metode: Penelitian ini menggunakan desain penelitian analitik observasional dengan pendekatan kohort prospektif. Data diperoleh dari anamnesis, pemeriksaaan fisik, dan lembar rekam medik pasien di RSUD Abdoel Wahab Sjahranie Samarinda pada rentang waktu Mei-Agustus 2024. Teknik pengambilan sampel menggunakan purposive sampling dan didapatkan 30 sampel.

Hasil: Hasil analisis bivariat menggunakan uji Wilcoxon didapatkan variabel ukuran tumor payudara (p=0.000), status kelenjar getah bening (p=0.000), dan kadar Estradiol (p=0.000).

Simpulan: terdapat perubahan yang signifikan antara ukuran tumor, status kelenjar getah bening, dan kadar Estradiol sebelum dan sesudah pemberian kemoterapi neoadjuvan berbasis taksan dan antrasiklin pada kasus kanker payudara stadium lokal lanjut Hormonal Positif.

 

Kata kunci: kanker payudara stadium lokal lanjut, kemoterapi neoadjuvan, taksan, antrasiklin


Keywords


kanker payudara stadium lokal lanjut, kemoterapi neoadjuvan, taksan, antrasiklin

Full Text:

PDF

References


American Cancer Society, A. (2020). Breast Cancer, Facts & Figures 2019-2020.

Angus L. (2021) GENOMICS-GUIDED PERSONALIZED CANCER TREATMENT BY MEANS OF TUMOR TISSUE, LIQUID BIOPSY AND RADIOMIC ANALYSES. Erasmus Unioversity Rotterdam.

Alkabban, F. M., & Ferguson, T. (2022). Breast Cancer Continuing Education Activity. https://www.ncbi.nlm.nih.gov/books/NBK482286/.

CDC. (2023). What Is Breast Cancer. https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm.

Chen, W., Zheng, R., Baade, P.D., & Zhang, S. (2016). Cancer Statistics in China , 2015. Ca Cancer J Clin, 66(2014), 115–132. https://doi.org/10.3322/caac.21338.

Chen, Y., & Qi, Y. (2023). Neoadjuvant chemotherapy for breast cancer : an evaluation of its ef fi cacy and research progress. Frontiers in Oncology, 1– 14. https://doi.org/10.3389/fonc.2023.1169010.

Choulli, F., Tafenzi, H.A., Hattimy, F.E., & Choulli, M. K. (2024). Chemotherapy- related adverse effects with anthracycline and taxane-containing regimens in patients with localized Breast cancer : a descriptive study. Open Access, 24(17), 1–8.

Clark, B.Z., Johnson, R.R., Berg, W.A., McAuliffe, P., & Bhargava, R. (2023). Response in axillary lymph nodes to neoadjuvant chemotherapy for breast cancers : correlation with breast response , pathologic features , and accuracy of radioactive seed localization. Breast Cancer Research and Treatment, 200(3), 363–373. https://doi.org/10.1007/s10549-023-06983-3.

Colomer, R., Saura, C., Sánchez-Rovira, P., Pascual, T., Rubio, I. T., Burgués, O., Marcos, L., Rodríguez, C. A., Martín, M., & Lluch, A. (2019). Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. The Oncologist, 24(5), 603–611. https://doi.org/10.1634/theoncologist.2018-0228.

Djannah, S.N., & Solikhah, S. (2019). Early Menarche with Breast Cancer Awareness: A Literature Review. Advances in Health Sciences Research, 18, 71–75. https://doi.org/10.2991/adics-phs-19.2019.14.

Folorunso, S.A., Abiodun, O.O., Salam, A.A.A., & Wuraola, F. O. (2023). Evaluation of side effects and compliance to chemotherapy in breast cancer patients at a Nigerian tertiary hospital. Ecancermedicalscience, 17, 1–10. https://doi.org/10.3332/ecancer.2023.1537.

Hilaj, E., Ymeri, A., & Shpati, K. P. (2020). The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy. Open Access, 12(2), 1–9. https://doi.org/10.7759/cureus.7117

Kang, Y.K., Si, Y.R., An, G.Y., & Yuan, P. (2021). Efficacy and safety of cyclophosphamide in anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer : a meta-analysis. Gland Surg, 10(1), 252–261. https://doi.org/10.21037/gs-20-593.

Mata, D.G.d.M.M., Rush, M.B., Uffen, M.S., & Younus, J. (2024). The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer — A Systematic Review and. Current Oncology, 31, 4486– 4506.

Roy, S., Lakritz, S., Schreiber, A.R., & Molina, E. (2023). Clinical outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A seer- medicare study. Elsevier, 1–29.

Suryaningsih, N.P.M., Yaniari, R., & Hernanda, P. Y. (2022). Systematic Literature Review of Early Estrogen Exposure and its Relation to Breast Cancer in Woman. Jurnal Ilmiah Kedokteran Wijaya Kusuma, 12(2), 182–192.

Vuger, A.T., Tiscoski, K., Apolinario, T., & Cardoso, F. (2022). Anthracyclines in the treatment of early breast cancer friend or foe ? The Breast, 65, 67–76. https://doi.org/10.1016/j.breast.2022.06.007.

Yu, C. C., Cheung, Y. C., Ueng, S. H., Lin, Y. C., Kuo, W. L., Shen, S. C., Lo, Y. F., & Chen, S. C. (2022). Factors Associated with Axillary Lymph Node Status in Clinically Node-Negative Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Cancers, 14 (18), 1–17. https://doi.org/10.3390/cancers14184451.

Zhen, H., Guo, F., Zhang, X., Jia, M., & Yang, H. (2020). The effects of chemotherapy with anthracyclines vs capecitabine on tumour size , survival rate and estradiol levels in patients with locally advanced breast cancer. European Journal of Gynaecological Oncology, 5, 785–789. https://doi.org/10.31083/j.ejgo.2020.05.5466.




DOI: http://dx.doi.org/10.30872/jkm.v11i2.17574

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 Jurnal Kedokteran Mulawarman

Creative Commons License
Jurnal Kedokteran Mulawarman by Faculty of Medicine Mulawarman University is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.